According to average of estimates of analysts polled by CNBC-TV18, revenue during the quarter may increase 11.6 percent year-on-year to Rs 7,905.3 crore, driven by Sun's authorised generic (AG) launches of Daichi Sankyo drugs in US.
first published: Feb 13, 2017 05:47 pm
A collection of the most-viewed Moneycontrol videos.
Rupee Slide Weighs Heavy As Nifty Tests 25,900| Midcaps See Sharp Cuts| Closing Bell Live
Meesho's Rs 5,421 Cr IPO Kicks Off| Post-IPO Playbook, Profitability Path & More| IPO Watch Live
Can Nifty Hold Above 26,000 Amid Currency Jitters? Meesho IPO Opens | Opening Bell Live
Nifty Struggles Below 26,100 On Weekly F&O Expiry As Rupee Hits New Low| Closing Bell Live
